

# **BactiVac Network Management Oversight Board (NMOB)**

# **Terms of Reference**

#### Overall remit:

The BactiVac Network Oversight Management Board (NMOB) is responsible for devising and reviewing BactiVac Network strategy, making decisions related to its implementation, based on recommendations from the Network Operations Management Group (NOMG), non-binding advice received from the Network Advisory Board (NAB) and appropriate input from the Full Membership. The NMOB is chaired by the Director of the Network who is accountable to the University of Birmingham Executive Board through the College Board.

#### **Terms of Reference:**

- 1. To advise and support the Directors of the BactiVac Network in the strategic management and leadership of the Network
- 2. To agree the plan for the management and delivery of the Network, including the dissemination of information, encouraging widespread, open membership
- 3. To facilitate communication and ensure the effective co-ordination of all matters relevant to the running of the BactiVac Network and its activities, including interactions with other appropriate national and international organisations
- 4. To monitor the Network's performance against all relevant targets and benchmarks, identifying action to encourage continuous improvement
- 5. To approve the distribution and awarding of Network funding, including reviewing applications submitted for funding under the Network's catalyst schemes
- 6. To review BactiVac Network's risk register, including identification of action required to mitigate threats and to exploit opportunities

#### **Duties of members of the NMOB:**

- To act in the best interests of the BactiVac Network
- To take collective responsibility for implementation of the NMOB's decisions
- To act in good faith and with integrity
- To exercise due care and diligence
- · To disclose and avoid any conflicts of interest
- To respect the confidentiality of those matters so classified
- Not to use their position to gain advantage for themselves or others
- Members are also expected to observe the 7 principles of public life identified by the Committee
  on Standards in Public Life (the Nolan Committee): selflessness, integrity, objectivity,
  accountability, openness, honesty, leadership.











**Membership:** The constitution of the NMOB will be reviewed on an annual basis and revised, if required, based on the needs of the Network in relation to any additional expertise required to successfully deliver the Network's strategy. The expectation is that members of the NMOB will actively engage with the Network and attend a minimum of one meeting each year. The tenure of membership is for the duration of the current funding period i.e. until 30/11/27.

Name	Position	Institution/Company	Expertise
Adam Cunningham (Chair)	Professor of Functional Immunology BactiVac Network Director	University of Birmingham, UK	Functional immunology, Mouse models
Constantino López- Macías	Head of the Medical Research Unit on Immunochemistry; BactiVac Network Co-Director	Mexican Institute for Social Security (IMSS), Mexico	Vaccine development in Latin America
Ankur Mutreja	Director of External Affairs and Health Security BactiVac Network Co-Director	PATH, India/UK	Conjugate, vesicle and whole cell killed vaccines, antibodies, mucosal immunology
Francesca Micoli	Director GVGH Innovation Academy – Senior Project Leader BactiVac Network Co-Director	GSK Vaccines Institute for Global Health, Siena, Italy	Vaccine development and delivery
Seanette Wilson	Science and Innovation Leader	Biovac Institute, Cape Town, South Africa	LMIC Vaccine Industry, DCVM
John McGiven	Senior Scientific Officer	APHA, UK	Veterinary vaccines and diagnostics
Alex Richter	Professor of Clinical Immunology	University of Birmingham, UK	Vaccine responses in Secondary Immunodeficiency
Jo Dean	BactiVac Network Operations Manager	University of Birmingham, UK	Operational and project management
Stephen Baker	Senior Principal Investigator	A* STAR, Singapore	Enteric infections research
Mark Stevens	Professor of Microbial Pathogenesis	The Roslin Institute, UK	Salmonella, E. coli and Campylobacter infections, pathogenesis and protection
Matt O'Shea	Clinical Professor of Infectious Diseases and Microbiology Consultant in Infectious Diseases and Clinical Microbiology Surgeon Commander, Royal Navy	University of Birmingham, UK	Infectious diseases and tropical medicine
Xin Tong	R&D Director	Walvax Biotechnology Co Ltd, China	Vaccine manufacture
V.Krishna Mohan	Executive Director	Bharat Biotech International, India	Vaccine manufacture
Adrian Shields	Clinical Lecturer	University of Birmingham, UK	Clinical immunology and antibody response
Pierre Balard* *Observer status	Research Lead, Vaccine Product Development	Wellcome, UK	Pre-clinical and clinical research
Phil Packer	Innovation Lead AMR and Vaccines	Innovate UK, UK	One Health approach to AMR, funding SMEs and industry to develop new vaccines, antimicrobials and therapies for infectious disease in both man and animals.
Kirsty Le Doare	Professor of Vaccinology and Immunology	Makerere University, Uganda St George's University of London, UK	Maternal immunization.











\*Observer status - An individual who is permitted to attend and participate in NMOB meetings and to receive all information provided to members of the NMOB (including minutes of NMOB meetings), but who is not permitted to formally vote on matters submitted for a vote.

The NMOB may invite any person to attend its meetings, subject to appropriate governance being place and with the approval of the Chair of the NMOB.

### **Network support**

- Jo Dean, Operations Manager
- Susan Pope, Deputy Operations Manager
- Jamie Pillaye, External Engagement Coordinator
- Annabel Haylor-Giles, Senior Events & Training Coordinator
- Georgia Homer, Administrator
- Alice Hodgson Copp, Marketing and Communications Assistant

## Frequency of meetings:

The NMOB will meet quarterly, with the aim of holding 1 meeting face to face each year (to coincide with the Annual Network Meeting).







